Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,841 to 3,860 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Arm 1 vs Arm 2: Primary Major Macrovascular Events | 264 of 899 235 of 892 | 3.0 points -1.1 to 7.2 | 1,791 | NCT00032487 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) |
| Arm 1 vs Arm 2: serious adverse events | 144 of 899 197 of 892 | -6.1 points -9.7 to -2.4 | 1,791 | NCT00032487 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) |
| Cardiac Resynchronization Therapy + Defibrillator vs Implantable Cardioverter Defibrillator Alone: serious adverse events | 164 of 1,079 55 of 712 | 7.5 points 4.5 to 10.3 | 1,791 | NCT00180271 MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy |
| 465 VADT Participants - Standard vs 465 VADT Participants -Intensive: The Long Term Effects of Intensive Glycemic Control in Type 2 Diabetes on the Secondary Outcome Cardiovascular Mortality. | 125 of 899 118 of 892 | 0.7 points -2.5 to 3.9 | 1,791 | NCT00756613 The VA Diabetes Trial Follow-up Study (VADT-FS) |
| 465 VADT Participants - Standard vs 465 VADT Participants -Intensive: The Long Term Effects of Intensive Glycemic Control in Type 2 Diabetes on the Secondary Outcome Total Mortality. | 366 of 899 376 of 892 | -1.4 points -6.0 to 3.1 | 1,791 | NCT00756613 The VA Diabetes Trial Follow-up Study (VADT-FS) |
| (SIIV+20vPnC)/Saline: Coadministration vs (SIIV+Saline)/20vPnC: Separate Administration: deaths from any cause | 2 of 895 3 of 896 | -0.1 points -0.8 to 0.5 | 1,791 | NCT04526574 Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age |
| (SIIV+20vPnC)/Saline: Coadministration vs (SIIV+Saline)/20vPnC: Separate Administration: serious adverse events | 33 of 895 33 of 896 | 0.0 points -1.8 to 1.8 | 1,791 | NCT04526574 Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age |
| Transdisciplinary Approach vs Multidisciplinary Approach: Dispensing of Psychotropic Medications | 107 of 487 227 of 1,303 | 4.5 points 0.5 to 8.9 | 1,790 | NCT03442322 Optimizing Care for Patients With Dementia |
| SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Married and Co-habiting With Husband [by Trial End Line] | 43 of 912 46 of 876 | -0.5 points -2.6 to 1.5 | 1,788 | NCT01996241 Evaluation of an Intervention for Adolescent Girls in Karnataka |
| SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Passing 10th Standard [Pass 10th Standard Exam] | 518 of 912 530 of 876 | -3.7 points -8.2 to 0.9 | 1,788 | NCT01996241 Evaluation of an Intervention for Adolescent Girls in Karnataka |
| SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Married [by Trial End Line] | 92 of 912 84 of 876 | 0.5 points -2.3 to 3.3 | 1,788 | NCT01996241 Evaluation of an Intervention for Adolescent Girls in Karnataka |
| SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Completing Secondary School [Sit 10th Standard Exam] | 680 of 912 658 of 876 | -0.6 points -4.6 to 3.5 | 1,788 | NCT01996241 Evaluation of an Intervention for Adolescent Girls in Karnataka |
| SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Having Sexual Debut [by Trial End Line] | 64 of 912 53 of 876 | 1.0 points -1.3 to 3.3 | 1,788 | NCT01996241 Evaluation of an Intervention for Adolescent Girls in Karnataka |
| CACHET - Ocular vs CACHET - Systemic: deaths from any cause | 0 of 1,123 3 of 657 | -0.5 points -1.3 to -0.0 | 1,780 | NCT01497067 Long Term Safety Protocol for the AcrySof CACHET Phakic Lens |
| CACHET - Ocular vs CACHET - Systemic: serious adverse events | 276 of 1,123 24 of 657 | 20.9 points 17.9 to 23.8 | 1,780 | NCT01497067 Long Term Safety Protocol for the AcrySof CACHET Phakic Lens |
| Cenicriviroc 150 mg vs Placebo: deaths from any cause | 6 of 1,185 2 of 593 | 0.2 points -0.8 to 0.8 | 1,778 | NCT03028740 AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) |
| Narrow Spectrum Antibiotic vs Non-narrow Spectrum Antibiotic: Symptoms Present on Day 3 | 427 of 1,128 267 of 647 | -3.4 points -8.2 to 1.3 | 1,775 | NCT02297815 Comparative Effectiveness of Antibiotics for Respiratory Infections |
| All TNFI Initiators Monotherapy vs Tofacitinib Initiators Combination: Number of Participants With mACR20 at 6 Months for Tofacitinib Combination With MTX vs TNFi Monotherapy | 394 of 1,683 19 of 90 | 2.3 points -7.4 to 9.8 | 1,773 | NCT05576051 To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting. |
| Cenicriviroc 150 mg vs Placebo: serious adverse events | 159 of 1,180 70 of 589 | 1.6 points -1.8 to 4.7 | 1,769 | NCT03028740 AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) |
| Inpatient vs Outpatient: Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient | 99 of 127 1,410 of 1,638 | -8.1 points -16.3 to -1.6 | 1,765 | NCT00605865 Drug Use Investigation of Jzoloft. |
Code
curl "https://conductscience.org/api/comparisons/v1?page=193"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=193
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00032487-6ac6ebfb",
"title": "Arm 1 vs Arm 2: Primary Major Macrovascular Events",
"summary": "264 of 899 against 235 of 892; risk difference 3.0 points, 95% interval -1.1 to 7.2; NCT00032487, Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)",
"record": "/library/comparisons/NCT00032487-6ac6ebfb",
"nct_id": "NCT00032487",
"kind": "outcome",
"participants": 1791,
"risk_difference": {
"value": 0.030206707003795963,
"lower": -0.011321739065687578,
"upper": 0.07158151726302422
},
"group_1": "264 of 899",
"group_2": "235 of 892",
"difference": "3.0 points",
"interval": "-1.1 to 7.2",
"trial_title": "Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)"
},
{
"id": "NCT00032487-sae",
"title": "Arm 1 vs Arm 2: serious adverse events",
"summary": "144 of 899 against 197 of 892; risk difference -6.1 points, 95% interval -9.7 to -2.4; NCT00032487, Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)",
"record": "/library/comparisons/NCT00032487-sae",
"nct_id": "NCT00032487",
"kind": "serious-adverse-events",
"participants": 1791,
"risk_difference": {
"value": -0.06067404240885488,
"lower": -0.09691048393792638,
"upper": -0.024321455113189984
},
"group_1": "144 of 899",
"group_2": "197 of 892",
"difference": "-6.1 points",
"interval": "-9.7 to -2.4",
"trial_title": "Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=194",
"request_id": "YguA3yz3QqJB_KyP"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant